慢性肾脏病中的性别与心血管结局
该叙述性综述总结女性CKD患者心血管疾病表型与结局不同于男性的生物学与诊疗因素。女性更常见射血分数保留的心衰和微血管功能障碍,男性更常见缺血性基质和射血分数降低的心衰。尽管女性透析前心血管死亡率较低,但相对风险随eGFR下降和蛋白尿增加而上升,透析后生存优势缩小。女性在CKD和心肾试验中代表性不足且治疗不足。
要点
- 女性CKD患者心衰多为射血分数保留型,与高血压、动脉僵硬和微血管功能障碍相关。
- 女性透析前心血管死亡率低于男性,但相对风险随eGFR下降和蛋白尿增加而上升。
- 女性在CKD和心肾试验中代表性不足,循证心肾治疗应用不足。
核心结论
- 女性CKD患者心血管疾病表型和结局与男性不同,涉及生物学因素和诊疗过程差异。
- 女性在CKD和心肾试验中代表性不足且治疗不足,需采取策略缩小性别差距。
研究设计与样本
- 叙述性综述,总结CKD各阶段和肾衰竭中CVD、血管功能障碍及治疗证据缺口的性别差异。
主要发现
- 女性CKD患者更常见射血分数保留的心衰和向心性重构,男性更常见缺血性基质和射血分数降低的心衰。
- 女性阻塞性冠脉事件较少,但无心外膜梗阻的缺血症状更多,与微血管功能障碍一致。
- 女性透析前CVD死亡率低于男性,但相对风险随eGFR下降和蛋白尿增加而急剧上升。
- 透析时女性生存优势缩小,心衰和卒中住院可能更多,尽管心血管死亡率略低。
- 妊娠期高血压疾病和生殖过渡(初潮、月经周期、绝经)塑造终生心肾风险轨迹。
临床怎么用
- 血压控制、他汀、RAAS阻断、醛固酮拮抗剂和SGLT2抑制剂有确切获益,但女性治疗不足。
局限性
- 为叙述性综述,未提供系统检索策略或定量合并分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Women with CKD have a high burden of cardiovascular disease (CVD), yet cardiovascular phenotypes and outcomes differ from men because of both biologic factors and care processes. Heart failure is common in CKD; women more often present with heart failure with preserved ejection fraction and concentric remodeling driven by hypertension, arterial stiffness, inflammation, and microvascular dysfunction, whereas men more commonly demonstrate ischemic substrates and systolic dysfunction, heart failure with reduced ejection fraction. Women tend to have fewer obstructive coronary events but more ischemic symptoms without epicardial obstruction, consistent with microvascular dysfunction compounded by CKD-related endothelial impairment. Although women generally show lower predialysis CVD mortality than men, relative risk rises sharply with declining eGFR and albuminuria and the female survival advantage narrows on dialysis, where women may have more heart failure and stroke hospitalizations despite slightly lower cardiovascular mortality. Female-specific exposures including hypertensive disorders of pregnancy and the reproductive transition such as menarche, menstrual cycles, and menopause, further shape life-long cardio-kidney risk trajectories. Despite proven benefits of blood pressure control, statins, renin-angiotensin-aldosterone system blockade, mineralocorticoid antagonists, and sodium-glucose cotransporter 2 inhibitors with emerging roles for incretin-based therapies, women remain undertreated and underrepresented in CKD and cardio-renal trials. Priorities include consistent sex-disaggregated reporting, improved heart failure phenotyping in CKD, mechanistic study of vascular dysfunction across CKD progression, and implementation strategies to close sex gaps in evidence-based cardio-renal care. This narrative review summarizes sex-based differences across CKD stages and kidney failure in CVD, vascular dysfunction, and therapeutic evidence gaps.
引用
- Shah S, Oh ES, Yerram P, et al. Sex and Cardiovascular Outcomes with CKD. Clin J Am Soc Nephrol. 2026. PMID: 42536413. doi:10.2215/CJN.0000001167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。